ORITAVANCIN
- Product Name
- ORITAVANCIN
- CAS No.
- 171099-57-3
- Chemical Name
- ORITAVANCIN
- Synonyms
- CS-2274;Orbactiv;LY 333328;ORITAVANCIN;Ollivan Star;brand name: Orbactiv;Oritavancin (LY333328);Oritavancin, trifluoacetate salt;Oritavancin (Lyophilized Powder For IV Infusion);rideoxy-3-methyl-α-L-arabino-hexopyranosyl)-β-D-g
- CBNumber
- CB92451283
- Molecular Formula
- C86H97Cl3N10O26
- Formula Weight
- 1793.1
- MOL File
- 171099-57-3.mol
ORITAVANCIN Property
- Density
- 1.59±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- pka
- 2.93±0.70(Predicted)
N-Bromosuccinimide Price
- Product number
- API0008111
- Product name
- ORITAVANCIN
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $496.02
- Updated
- 2021/12/16
ORITAVANCIN Chemical Properties,Usage,Production
Definition
ChEBI: A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.
Clinical Use
Antibacterial agent
Enzyme inhibitor
This novel, semi-synthetic glycopeptide antibiotic (FW = 1793.10 g/mol; CAS 171099-57-3), also known as LY333328, Orbactiv?, and (4R)-22-O- (3-amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(pchlorophenyl) benzyl)vancomycin, disrupts the cell membrane of Grampositive bacteria and inhibits both transglycosylation and transpeptidation. Oritavancin differs from vancomycin by the presence of a hydrophobic N-4-(4-chlorophenyl)benzyl substituent on the disaccharide, the addition of a 4-epi-vancosamine monosaccharide to the amino acid residue in Ring-6, and replacement of the vancosamine moiety by 4-epi-vancosamine. When compared vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillinresistant methicillinresistant Staphylococcus aureus, LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Indeed, a single infusion of this antibiotic (1200 mg) can clear serious bacterial skin infections, including methicillin-resistant Staphylococcus aureus, or MRSA, as effectively as the usual 7-10 day, twice-daily regimen of vancomycin now needed to treat patients.
Drug interactions
Potentially hazardous interactions with other drugs
Anticoagulants: possibly increases warfarin
concentration.
Metabolism
In vitro human liver microsome studies indicated that oritavancin is not metabolised. It is excreted unchanged; less than 1% and 5% of a dose is recovered in the urine and the faeces.
ORITAVANCIN Preparation Products And Raw materials
Raw materials
Preparation Products
ORITAVANCIN Suppliers
- Tel
- --
- Fax
- --
- Country
- India
- ProdList
- 27
- Advantage
- 58
View Lastest Price from ORITAVANCIN manufacturers
- Product
- ORITAVANCIN 171099-57-3
- Price
- US $0.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 2000ton
- Release date
- 2023-09-07
- Product
- ORITAVANCIN 171099-57-3
- Price
- US $12.00/g
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 5ton/Month
- Release date
- 2021-11-22
- Product
- ORITAVANCIN 171099-57-3
- Price
- US $20.00/KG
- Min. Order
- 1KG
- Purity
- 99
- Supply Ability
- 999
- Release date
- 2020-10-26